#1968 - TAFRO syndrome with glomerulonephritis ; The first case from Iran	
Authors and Affiliations	1. Mohaddess Seyede Tahereh, Assistant Professor ,Devision of hematology oncology, department of internal medicine, faculty of medicine, Mashhad university of medical sciences, Mashhad ,Iran. Tel: +989122526739. Email:mohaddest@mums.ac.ir. 2. Rezaei Borojerdi Zahra, Internal medicine resident, Devision of hematology oncology, department of internal medicine, faculty of medicine, Mashhad University of Medical Sciences, Mashhad,Iran. Tel: +989155598170, Email: Drzr358@gmail.com. 3. Moeini Nodeh Mohammad, Hematology Oncology fellowship, Devision of hematology oncology, department of internal medicine, faculty of medicine, Mashhad, Iran. Tel: +989155000604, Email: moeininm951@mums.ac.ir. 4. Rezaei Alireza, Anatomical clinical Pathologist, Assistant Professor, Islamic Azad University of Medical Sciences, Mashhad, IR Iran. Tel: +989155177196, Email: Alireza-rezaei74@mshdiau.ac.ir. 5. Ghorban Sabbagh Mahin, Assistant Professor, Kidney transplantation complication research center, mashhad university of medical science, mashhad, Iran. Tel: +989153156967. Email:sabbaghm@mums.ac.ir. 6. Sajjadi Samane, Hematology oncology fellowship, Mashhad University of medical sciences, Mashhad, Iran. Tel:+989151024463, Email:sajjadis@mums.ac.ir. 7. Seyyedi Khabbaz Fatemeh, Hematology & medical oncology fellowship, Mashhad University of medical sciences, faculty of medicine. Mashhad, Iran. Tel: +989155583845, Email: Beetaseyyedi@gmail.com. 8. Ranjbar Amin, Internal medicine resident, Mashhad University of medical sciences, faculty of medicine, Mashhad, Iran. Tel: +989155114553, Email: ranjbara941@mums.ac.ir.
Corresponding Author and email	Zahra Rezaei Borojerdi, Address: no: 17, hashemieh 83, hashemieh boulevard, vakilabad boulevard, Mashhad, Iran ,Tel: +989155598170, Fax: 38453239
Body	Objectives: TAFRO syndrome is a new presentation of

idiopathic multicentric Castleman disease which is termed as thrombocytopenia, anasarca, fever, reticulin myelofibrosis and organomegaly. The exact pathophysiology of TAFRO syndrome is unclear and management is mostly based on case reports and expert opinion. Methods: Histologic findings of bone marrow, skin, kidney and lymph node biopsy and other laboratory findings of the 37 year old male has been provided. Results: The patient was referred with fever, sweating, anorexia, abdominal distension and generalized edema. The patient also developed skin lesions dispersed in red nodules, which was reported as "granuloid hemangioma". Renal biopsy reported mesangioprolifrative glomerulonephritis and bone marrow specimen showed hypercellular marrow with reticulin fibrosis. The lymph node biopsy was reported as Castleman disease. Conclusions: Different manifestations of TAFRO syndrome may overlap with other syndromes and can be managed by corticosteroids, tocilizumab, retuximab, and bortezomib Key-words: Castleman disease; hemangioma; glomerulonephritis

References

1. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004 Dec 1; 43(8):698-704. 2. Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016 Jun 1; 103(6):686-92. 3. Dispenzieri A. P OEMS syndrome: 2017 Update on diagnosis, risk stratification, and management. Am J Hematol. 2017 Aug; 92(8):814-29. 4. Noda-Narita S, Sumida K, Sekine A, Hoshino J, Mise K, Suwabe T, et al. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN case Rep. 2018 May 1:1-7. 5. Aoki T, Wada M, Kawashima A, Hirakawa K, Nagata A, Kagawa K. Tocilizumab-resistant TAFRO Syndrome Complicated by Type II Respiratory Failure. Intern Med. 2017 Dec 1; 56(23):3249-54. 6. Kikuchi T, Shimizu T, Toyama T, Abe R, Okamoto S. Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide. Intern Med. 2017 Aug 15; 56(16):2205-11. 7. Igawa T, Sato Y. TAFRO Syndrome. Hematol Oncol Clin North Am. 2018; 32(1):107-18. 8. Louis C, Vijgen S, Samii K, Chalandon Y, Terriou L, Launay D, et al. TAFRO syndrome in Caucasians: a

case report and review of the literature. Front Med. 2017 Sep 22; 4: 149. 9. Van Rhee F, Greenway A, Stone K. Treatment of Idiopathic Castleman Disease. Hematol Oncol Clin North Am. 2018 Feb 28; 32(1):89-106. 10. Lin Q, Fang B, Huang H, Yu F, Chai X, Zhang Y, et al. Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease. Blood Cancer J. 2015 Mar; 5(3):e298.. 11. Yuan ZG, Dun XY, Li YH, Hou J. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report. J HematolOncol. 2009 Dec; 2(1):19.

Generate date	03 November 2018 14:49